Martine Piccart

Nov 3, 2023 | nature.com | Mattia Rediti |Katherine A. Hoadley |Joel Parker |David Hillman |Martine Piccart |Serena Di Cosimo | +6 more

AbstractThe identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity of B and T cell receptor (BCR and TCR) repertoires in the context of two phase III trials, NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women with HER2-positive breast cancer.